Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
about
Heart failure hospitalization risk associated with use of two classes of oral antidiabetic medications: an observational, real-world analysis.Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner?Dapagliflozin acutely improves endothelial dysfunction, reduces aortic stiffness and renal resistive index in type 2 diabetic patients: a pilot study.Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats.Cardioprotective anti-hyperglycaemic medications: a review of clinical trials.Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.Role of the sodium-hydrogen exchanger in mediating the renal effects of drugs commonly used in the treatment of type 2 diabetes.Mechanistic Insights of Empagliflozin-Mediated Cardiac Benefits: Nearing the Starting Line : Editorial to: "Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes" by N. Hammoudi et al.Un-sweetening the Heart: Possible pleiotropic effects of SGLT2 inhibitors on cardio and cerebrovascular alterations in resistant hypertensive subjects.Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.Dual inhibition of sodium–glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
P2860
Q41176211-87120B1E-3453-417B-B47B-B77E7A98D87CQ42334747-73B2288C-4218-44BC-A425-DF323A7747A3Q42643495-0EF90F0B-BF36-4546-BF3E-C64B4D4752A7Q45337526-650B7272-6F53-4F02-B740-1CA6CDF6A7F1Q47297477-F6DD6F21-137B-4001-8F14-C71D1963F4A8Q47739163-BAB473BF-2CD1-4F57-B82B-B499842E3944Q48141985-A9EB023D-82CE-4BF4-8829-DDC45AFB5A7AQ48363461-F34A9244-A53C-4AA4-8163-A91D859530F6Q49550551-A42D68B2-CE68-43FB-AE76-46EF73820B02Q55332339-A1D5C8F8-B9B6-4C1D-9E32-59867DEAC39FQ55457178-A8C6440F-97DD-4C77-BF1D-2DA54B68BC37
P2860
Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Empagliflozin lessened cardiac ...... rats with metabolic syndrome.
@en
type
label
Empagliflozin lessened cardiac ...... rats with metabolic syndrome.
@en
prefLabel
Empagliflozin lessened cardiac ...... rats with metabolic syndrome.
@en
P2093
P2860
P1476
Empagliflozin lessened cardiac ...... rats with metabolic syndrome.
@en
P2093
Hiroaki Kusaka
Hisao Ogawa
Nobutaka Koibuchi
Shokei Kim-Mitsuyama
Yu Hasegawa
P2860
P2888
P356
10.1186/S12933-016-0473-7
P407
P577
2016-11-11T00:00:00Z
P6179
1044950428